ABBOTT INDIA LIMITED

TriClip, Abbott's device, is the second FDA-approved treatment for tricuspid regurgitation (TR), following Edwards Lifesciences' Evoque TTVR system. Numerous other T-TEER and TTVR devices are in development. CMS is evaluating Medicare coverage for T-TEER, accepting public comments until Nov. 2, 2024, with a decision expected by July 2025. Abbott is optimistic about CMS's recognition of TR treatment importance.

The global anti-infective drugs market was valued at US$ 139.1 Bn in 2022 and is projected to reach US$ 177.9 Bn by 2031, growing at a CAGR of 4.0% due to rising infectious disease incidence, hygiene awareness, drug development advancements, and antimicrobial resistance.

Digital health investors David Buller and Laurent van Lerberghe launch KELES, a €250m venture capital firm focusing on European growth-stage digital health companies. KELES aims to bridge the gap between startup innovation and global impact, with investment tickets ranging from €8M-€30M. The firm, with bases in Paris, London, Brussels, and Luxembourg, is on track for its first close in Q1 2025, targeting high-potential scale-ups addressing healthcare challenges.

September 2024 saw FDA approvals for Embecta's tubeless insulin patch pump, Ascensia and Senseonics' Eversense 365 CGM, and Ascendis Pharma's TransCon hGH for GHD. The American Society of Nephrology issued guidance on obesity management in kidney disease patients, and data from EADV Congress 2024 showed semaglutide's benefits in obesity patients. A study matched GLP-1 RA users with MASLD and type 2 diabetes to lower cirrhosis risks. Diabetes Dialogue discussed Dexcom Stelo's OTC glucose sensor and Abbott's Lingo availability.

CMS accepted a formal request for a national coverage analysis (NCA) for Abbott's TriClip, a transcatheter edge-to-edge repair system for treating tricuspid valve regurgitation. The NCA falls under the Transitional Coverage of Emerging Therapy (TCET) pathway and includes a 30-day public comment period. Analysts expect a completed NCA by July 2, 2025.

2024 saw significant advancements in neurotech, including FDA approvals, mergers, and innovations like Axonics' neuromodulation systems, Medtronic's Liberta RC DBS, Neuralink's BCI implants, Cognito's non-invasive Alzheimer's therapy, and Synchron's AI-enhanced BCI. DeviceTalks West featured neurotech innovations.

SeeHer, an initiative by the ANA, unveiled a 30-second ad featuring Gen Alpha girls as strong and confident, aiming to inspire marketers to represent women accurately. SeeHer also launched a health and wellness guide for healthcare marketers, emphasizing the importance of realistic female representation in ads, as women are key decision-makers in 80% of healthcare choices.

FDA clears digital therapeutic DaylightRX for GAD, approves updated Novavax COVID-19 vaccine, and clears Embecta's disposable insulin patch pump. Big 3 PBMs control US drug supply chain, NCPA urges CMS for PBM protection, and Cigna's Express Scripts sues FTC. FTC counters with lawsuit against 'Big 3' PBMs for insulin price inflation. Abbott's OTC Lingo CGM available, Vaxcyte announces positive data for 31-valent pneumococcal vaccine, and AI-optimized cash pricing aids pharmacies.

Breast cancer treatment market employs various drugs, including chemotherapy, hormone therapies, targeted therapies, and immunotherapy. Market growth is driven by increased incidence, research advancements, early detection awareness, personalized medicine, and new drug classes. The market is projected to reach USD 49.2 billion by 2032, with major companies like Abbott, Merck, GSK, Novartis, Johnson & Johnson, Bristol-Myers Squibb, Sun Pharmaceutical, Pfizer, Teva Pharmaceutical, and AbbVie leading in innovation and geographical expansion.

Synergia Medical implants first patients in epilepsy study using optical fibre-based neurostimulation, addressing MRI compatibility issues in current metal wire devices.